Piper Sandler Initiates Coverage On Jasper Therapeutics with Overweight Rating, Announces Price Target of $2

Benzinga Newsdesk www.benzinga.com Neutral 51.7%

Neg 0% Neu 51.7% Pos 0%

Piper Sandler analyst Biren Amin initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Overweight rating and announces Price Target of $2.